Trial Profile
A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs Citarinostat (Primary) ; Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Acetylon Pharmaceuticals; Celgene Corporation
- 25 Feb 2020 Status changed from active, no longer recruiting to completed.
- 10 Jun 2019 Planned End Date changed from 5 Jul 2018 to 31 Dec 2019.
- 10 Jun 2019 Planned primary completion date changed from 5 Jul 2018 to 30 Nov 2019.